Abstract

Objective: To assess use of stress ulcer prophylaxis in patients admitted to five pediatric intensive care units (PICUs) in Porto Alegre, Brazil.

Methods: This was a multicenter, prospective, cross-sectional observational study. PICUs were visited on randomly defined days between April 2006 and February 2007, and the medical records of admitted patients were reviewed. Patients whose records had been previously assessed were excluded, as were those with upper gastrointestinal bleeding on admission. Data were collected on age, gender, admission diagnosis, severity of illness, administration of stress ulcer prophylaxis, rationale for prophylaxis, and first-line prophylactic agent of choice. Variables were described as absolute and relative frequencies, mean and standard deviation, or median and interquartile range as appropriate. Pearson’s chi-square test for linear trend or Fisher’s exact test were used to assess possible associations. The level of significance was set at 5% (p ≤ 0.05).

Results: 398 patients (57% male) were assessed [median age, 16 months (IQR 4-65); median length of PICU stay, 4 days (IQR 1-9)]. Respiratory illness was the main reason for admission (32.7%). Most patients received stress ulcer prophylaxis (77.5%; range, 66-91%). Mechanical ventilation (22.3%) was the most common rationale provided, followed by informal routine use of prophylaxis (21.4%). Only one of the participating PICUs had a specific care protocol for use of stress ulcer prophylaxis. Ranitidine was the most commonly used drug (84.5% of cases). Evidence of minor gastrointestinal bleeding was found in 3% of patients; none had clinically significant bleeds.

Conclusions: Administration of stress ulcer prophylaxis is a common practice in the participating PICUs, with ranitidine the most commonly used drug. Among the various rationales provided, mechanical ventilation and informal routine use were the most prevalent.


Introduction

Critically ill patients are at risk of stress-related mucosal disease (SRMD), which leads to increased morbidity and mortality in the intensive care unit (ICU) setting. In pediatric patients, the prevalence of stress ulcer-related gastrointestinal bleeding ranges from 6 to 43%, with major bleeding rates as high as 1.6 to 5.3%.1

Although the pathophysiology of SRMD has yet to be fully elucidated, factors involved in its etiology include decreased gastric pH, increased permeability of the gastric mucosa, and ischemia.2 When gastric pH rises above 3.5-4.0, the frequency of SRMD and upper gastrointestinal bleeding declines significantly.3

2. Doutora, Gastroenterologia. UFRGS, Porto Alegre, RS, Brazil. Unidade de Gastroenterologia Pediátrica, Serviço de Pediatria, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil.

No conflicts of interest declared concerning the publication of this article.

Manuscript submitted Jul 26 2010, accepted for publication Sep 22 2010.
doi:10.2223/JPED.2046
Several studies have suggested that mechanical ventilation (MV) is one of the most significant of various probable risk factors for this condition, both in adults and children admitted to intensive care.\textsuperscript{4–6} A study by Chaibou et al. found three independent risk factors for major upper gastrointestinal bleeding in critically ill children: respiratory failure [odds ratio (OR) = 10.2], coagulopathy (OR = 9.3), and a pediatric risk of mortality (PRISM) score ≥ 10 (OR = 4.0).\textsuperscript{5} The PRISM score assesses several clinical and laboratory parameters and is used to predict mortality in the pediatric intensive care unit (PICU) environment.

Drugs commonly used for stress ulcer (SU) prophylaxis include antacids, sucralfate, H\textsubscript{2} receptor antagonists, and proton pump inhibitors,\textsuperscript{7} and their use should be restricted to patients with risk factors for stress ulcer.

Few studies have assessed the prevalence of SRMD/SU prophylaxis in pediatric patients. Most studies date back to the 1990s, and none have been conducted in Brazil.\textsuperscript{5,6} SU prophylaxis has been associated with major complications, such as hospital-acquired pneumonia, particularly in critically ill patients.\textsuperscript{8} Establishing a profile of SU prophylaxis administration in a certain population is therefore an important part of any thorough review of the appropriateness of this intervention.

The objective of the present study was to assess the prevalence of SU chemoprophylaxis in patients admitted to ICUs in the city of Porto Alegre, state of Rio Grande do Sul, Brazil, and identify the main rationales provided for prophylaxis and the drug most commonly used for this purpose.

**Methods**

This was a prospective, cross-sectional, observational study conducted at five mixed medical/surgical PICUs in the city of Porto Alegre, including one located at a trauma center and one at a center of excellence in cardiac surgery. These five PICUs had a total of 64 beds, which are available to patients covered by the Brazilian Unified Health System (UHS) as well as private uninsured patients and those with health insurance. All PICUs were located at teaching hospitals. The study was approved by the Research Ethics Committees of all participating hospitals. As this is a purely observational study with a chart review design, nearly all ethics committees agreed that informed consent would not be required, with the authors expressing a commitment to signing a patient confidentiality form (covering identifying information and other data) instead. One participating institution, however, believed informed consent was in order; consent was therefore obtained from all patients enrolled from this hospital.

A review was conducted of the charts of all patients receiving care at the participating PICUs on the day of visitation. PICUs were visited on randomly defined days between April 2006 and February 2007.

The exclusion criteria were: age > 18 years; evidence of prior upper gastrointestinal bleeding; current history of epistaxis, facial trauma, or other injuries or factors that could be mistaken for gastrointestinal bleeding; diagnosis of brain death on admission; assessment on prior occasions; long-term hospital stay (> 1 year); use of stress ulcer prophylaxis prior to PICU admission; and refusal of informed consent (in the hospital where it was required).

Data collected included age, gender, diagnosis on admission, disease severity, length of PICU stay at the time of assessment, use of stress ulcer prophylaxis and/or treatment for upper gastrointestinal bleeding, switching of drugs used for either purpose, and presence of gastrointestinal bleeding during PICU stay up to the time of assessment. Data were collected from patient records; in the event of conflicting, unclear, or missing data, attending physicians were contacted for clarification. Visits were performed at random, without prearrangement with any treating physicians and with no interference on the choice to administer stress ulcer prophylaxis.

Due to a substantial difference in number of beds, one of the participating PICUs was subdivided into two virtual units for ease of data analysis and to avoid identification. The ICU with a distinctively greater number of beds was therefore analyzed as two separate units for the purposes of this study; accordingly, results are reported for six, not five, PICUs.

Upper gastrointestinal bleeding was defined as any episode of hematemesis, melena, or hematochezia; aspiration of any volume of blood through a nasogastric (NG) tube; or drainage of bloody or coffee-ground stomach contents from an NG tube.\textsuperscript{5,9} Upper gastrointestinal bleeding was defined as clinically important if hypotension, death, or a need for blood transfusion developed within 24 hours of bleeding.\textsuperscript{5} Patient severity was assessed according to multiple organ dysfunction syndrome (MODS) criteria as defined by Proulx et al.\textsuperscript{10} Mortality risk scores, such as the pediatric index of mortality (PIM) or PRISM, were not taken into account when classifying patients by severity, as use and choice of risk scores was not standardized among the participating institutions. It would thus be impossible to compare the disease severity of patients admitted to different PICUs using these scores as parameters.

The sample size for an estimated proportion of 50% of patients receiving SRMD prophylaxis was calculated as 385 patients, with a 95% confidence interval and a margin of error of 5%. Data were entered into a Microsoft Office Excel spreadsheet and statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS) 14.0 software package. Categorical variables were expressed as absolute and relative frequencies and quantitative variables as mean and standard deviation (for apparently symmetric
distributions) or median and interquartile range (IQR) (for asymmetric distributions). Pearson’s chi-square test for linear trend or Fisher’s exact test were used as appropriate to evaluate associations between variables. The significance level was set as 5% ($p \leq 0.05$).

**Results**

Over the course of the study period, 561 patients were admitted to and treated in the participating PICUs; 122 of these were removed from the sample as they met one or more of the aforementioned exclusion criteria. This left 398 patients, 57% of whom were male. Median age was 16 months (IQR, 4–65 months) and median length of PICU stay at the time of assessment (that is, time elapsed between PICU admission and assessment) was 4 days (IQR, 1–9 days).

The most common diagnoses at admission were respiratory illness (32.7%), postoperative recovery (30.9%), trauma (12.8%), and heart disease (6.8%). Other diagnoses accounted for less than 5% of cases each.

The overall prevalence of SU prophylaxis was 77.5% ($n = 309$; range, 66 to 91%). Figure 1 shows the distribution of SU prophylaxis across the participating PICUs. Overall, at the time of review, 68% of patients ($n = 271$) were receiving some prophylactic agent, whereas 9.5% ($n = 38$) had previously received prophylaxis at some point over the course of their ICU stay.

Classification of patients by severity showed that respiratory failure (61%), cardiac dysfunction (38.2%), and coagulopathy (16.3%) were most prevalent. Table 2 presents a breakdown of patients by severity and PICU, showing that patients in PICU 2 were more severely ill ($p < 0.001$). Among patients with respiratory failure, 85.2% received prophylaxis; conversely, 10% had been given no prophylactic drugs whatsoever as of the time of assessment, even though prophylaxis was indicated. Prophylaxis was given to 86.2% of patients with coagulopathy, whereas 4.6% of those in this group did not receive it.

Analysis of severity also showed that use of prophylaxis increased with the number of organ systems affected, as shown in Figure 2. Among patients with multiple organ dysfunction affecting four or more systems ($n = 10$), two were no longer receiving prophylaxis, but treatment (due to evidence of upper gastrointestinal bleeding) instead. It is important to note that the number of patients in each group declined as the number of affected organ systems increased. Choice to administer SU prophylaxis was directly associated with increased number of organ systems with altered function (chi-square test for linear trend = 36.2; $p < 0.001$).

<table>
<thead>
<tr>
<th>Rationale</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanical ventilation</td>
<td>69 (22.3)</td>
</tr>
<tr>
<td>Routine use</td>
<td>66 (21.4)</td>
</tr>
<tr>
<td>Severe condition</td>
<td>44 (14.2)</td>
</tr>
<tr>
<td>S/P cardiac surgery</td>
<td>36 (11.7)</td>
</tr>
<tr>
<td>No reason/unknown</td>
<td>22 (7.1)</td>
</tr>
<tr>
<td>Head trauma</td>
<td>21 (6.8)</td>
</tr>
<tr>
<td>S/P neurosurgical intervention</td>
<td>12 (3.9)</td>
</tr>
<tr>
<td>Transplant</td>
<td>8 (2.6)</td>
</tr>
<tr>
<td>Burn(s)</td>
<td>7 (2.3)</td>
</tr>
<tr>
<td>Coagulopathy</td>
<td>2 (0.6)</td>
</tr>
<tr>
<td>Other*</td>
<td>22 (7.1)</td>
</tr>
</tbody>
</table>

* Epigastric pain, gastroesophageal reflux, vomiting, absence of enteral feeding, general postoperative recovery, recommended by specialist/attending physician.

---

**Table 1 - Rationales provided for ordering stress ulcer prophylaxis ($n = 309$)**

---

**Figure 1 - Percentage of patients receiving stress ulcer prophylaxis at each PICU**

The main rationales for prophylaxis were mechanical ventilation (22.3%) and routine use (21.4%). Other rationales are listed in Table 1. The term “severe condition” was used by the physician on call to justify SU prophylaxis when no specific rationale was listed on the patient’s chart but the physician believed the patient had multiple factors to warrant administration of prophylaxis. For the purposes of this study, “routine use” refers to informal practice alone, not guideline- or protocol-based use, and generally included rationales such as respiratory stress, corticosteroid use, or some postoperative settings.

Ranitidine was used most commonly for prophylaxis (84.5% of cases), followed by omeprazole as the sole alternative.
Table 2 - Distribution of patient severity (according to number of affected organ systems) by PICU

Table 2 - Distribution of patient severity (according to number of affected organ systems) by PICU

<table>
<thead>
<tr>
<th>PICU</th>
<th>None</th>
<th>One</th>
<th>Two</th>
<th>Three</th>
<th>Four</th>
</tr>
</thead>
<tbody>
<tr>
<td>PICU 1</td>
<td>37.3</td>
<td>25.5</td>
<td>15.7</td>
<td>19.6</td>
<td>2</td>
</tr>
<tr>
<td>PICU 2</td>
<td>14.3</td>
<td>23.8</td>
<td>29.8</td>
<td>26.2</td>
<td>6</td>
</tr>
<tr>
<td>PICU 3</td>
<td>28.9</td>
<td>26.3</td>
<td>30.3</td>
<td>9.2</td>
<td>5.3</td>
</tr>
<tr>
<td>PICU 4</td>
<td>51</td>
<td>30.6</td>
<td>16.3</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>PICU 5</td>
<td>31.1</td>
<td>33.3</td>
<td>24.4</td>
<td>11.1</td>
<td>0</td>
</tr>
<tr>
<td>PICU 6</td>
<td>46.2</td>
<td>23.7</td>
<td>23.7</td>
<td>6.5</td>
<td>0</td>
</tr>
</tbody>
</table>

PICU = pediatric intensive care unit.

Discussion

The overall profile of patients included in our sample was similar to that of other studies conducted in the PICU setting.\textsuperscript{11-15} Use of SU prophylaxis was highly prevalent in all participating institutions, with 77.5% of patients receiving prophylaxis at some point during their PICU stay. Our review of then literature showed that only two prior studies provided information on the prevalence of SU prophylaxis in children; these reported prevalence rates of 11 and 14.5% respectively, with use of prophylaxis restricted to high-risk patients.\textsuperscript{5,6} No pediatric studies on SRMD prophylaxis have been conducted in Brazil. The only investigation on the subject conducted in the country was carried out in an adult ICU, and reported that 73.5% of patients received SU prophylaxis – a rate very similar to that found in the present study.\textsuperscript{16}

The prevalence of prophylaxis administration in our sample of PICUs ranged from 66 to 91%. The unit in which the highest rate was found considers SU prophylaxis a routine intervention to be used in nearly all patients admitted to intensive care. Interestingly, the unit in which prophylaxis was least prevalent was also the only one that had a formal protocol in place for stress ulcer prophylaxis. Even so, prophylaxis was prescribed often.

According to the current literature, the most prevalent risk factors for upper gastrointestinal bleeding in critically ill patients are respiratory failure/mechanical ventilation and coagulation disorders.\textsuperscript{2,5,6,17} The incidence of clinically important (major) upper gastrointestinal bleeding is so low in patients with one or no risk factors (0.1%) that SU prophylaxis would be entirely unwarranted in this group; it has been suggested that prophylaxis be indicated only in patients with two out of these three risk factors.\textsuperscript{6}

Mechanical ventilation was clearly regarded as a major indication for prophylaxis by the physicians in our sample; it was the main rationale provided (22.3%), alongside routine use (21.4%). The very presence of a “routine use” category, representing purely habitual practice unrelated to any formal institutional care protocols, suggests that standardized, evidence-based management is absent. Other, less representative indications included administration of prophylaxis for no identifiable reason (7%) and other reasons (also 7%; these included epigastric pain, gastroesophageal reflux, vomiting, absence of enteral feeding, general postoperative care, and discretionary use by the attending physician).

In the present study, coagulopathy was provided as the rationale for SU prophylaxis in only two patients (0.6%). This may be considered an underestimate, as most patients had more than one reason for prophylaxis in the assessment of the ICU physician; these patients were included in the “severe condition” category. Alternately,
some may have been placed in the "post cardiac surgery" category and given anticoagulant therapy. Other reasons for prophylaxis mentioned in this study were head trauma, major burns, status post neurosurgical intervention, and organ transplantation; these have also been mentioned as reasons in other studies.\(^\text{18}\)

A lack of precise criteria for indicating prophylaxis in adults has also been established: one study showed that 25.7% of high-risk patients were not given SU prophylaxis even as 71.4% of low-risk patients received it.\(^\text{16}\)

Studies have shown that critical care specialists are aware of the risk factors associated with SU in ICU patients. There is, however, a disconnect between this awareness and the choice to administer prophylaxis, as shown by the fact that, even after correct identification of at-risk patients, some physicians recommend prophylaxis for all those admitted to intensive care.\(^\text{2,19}\)

In this study, ranitidine was the main drug used for SU prophylaxis: it was the first choice of therapy in 84.5% of cases. This predominance of ranitidine use has been reported elsewhere in the literature.\(^\text{15,19,20}\) Some authors claim that elevation of stomach pH levels above a threshold value is an appropriate intervention for prevention of upper gastrointestinal bleeding, although not all clinically important bleeds can be prevented by gastric pH control.\(^\text{21}\) The primary objective of acid suppression therapy is to prevent SRMD by keeping gastric pH above 4.0. Increasing pH to this level, however, proves inadequate in patients with acute upper gastrointestinal bleeding or those at risk of rebleeding after successful hemostasis. The level of stomach pH control provided by PPIs has proved superior to that achieved by H\(_2\) blockers, which produce early tolerance and loss of antisecretory effect (usually as early as the second or third day of administration), and may therefore be inadequate for critically ill patients.\(^\text{22}\)

In addition to being the first choice of medication for SU prophylaxis in the participating institutions, ranitidine was and is administered for long periods, usually for the duration of the patient’s PICU stay, with no consideration given to stomach pH management or development of tolerance to the drug.\(^\text{21}\)

In all participating PICUs, use of prophylaxis was found to increase with the number of organ systems with altered function. All patients with multiple organ dysfunction syndrome (affecting four or more systems) were administered prophylaxis. The 20% such patients who were not actively receiving prophylaxis (Figure 1) had an established diagnosis of upper gastrointestinal bleeding and had been switched to treatment instead. It is extremely important to stress that 47.4% of patients receiving prophylaxis had no degree of organ system dysfunction whatsoever.

The present study confirmed the hypothesis that SU prophylaxis is highly prevalent in Brazil, and could, according to the available literature, be considered inappropriate in many situations. Prophylaxis should be administered to patients with the above-described risk factors and maintained until these factors have resolved; physicians should bear in mind that the use of certain prophylactic agents may lead to drug tolerance, drug-drug interactions, and infectious complications. We believe the use of a formal care protocol containing well-established criteria and indications for SU prophylaxis could substantially reduce its prevalence and, consequently, cut costs and reduce the potential for associated complications.

We are aware of the limitations of this study; its cross-sectional design provides an idea of how prophylaxis is being used in the study environment alone. Therefore, we suggest that further studies be undertaken to identify risk factors associated with the need for SU prophylaxis and determine the best choice of medication for SU prophylaxis in critically ill pediatric patients.

**Acknowledgements**

The authors would like to thank the staff and Chiefs of the five participating pediatric intensive care units for their assistance: Dr. Eliana de Andrade Trota of the Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS); Dr. Cláudia Pires Ricachinevsky of the Hospital da Criança Santo Antônio, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA); Dr. Policarpo Blanco Lopez of the Hospital de Pronto Socorro Municipal de Porto Alegre; Dr. Maria Helena Lovato Dellazzana of the Hospital Materno Infantil Presidente Vargas; and Dr. Pedro Celiny Ramos Garcia of Hospital São Lucas, Pontificia Universidade do Rio Grande do Sul (PUCRS). We also extend our gratitude to the patients included in this study and to their families.

**References**


Correspondence:
Taisa Elena de Araujo
Rua Vasco da Gama, 1208/401 – Rio Branco
CEP 90420-110 – Porto Alegre, RS – Brazil
Tel.: +55 (51) 9115.2503
Fax: +55 (51) 3207.9666
E-mail: taisaelena@terra.com.br